Researchers screened 2,000 Nigerian women with and without the disease for loss-of-function mutations in 25 known and suspected breast cancer genes.
Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.
The Wall Street Journal reports that men seek genetic testing for inherited BRCA1 or BRCA2 mutations much less often than women.
DeCode's new offering adds to an ongoing controversy over whether people in the island country have a right to know if they are at increased risk for disease.
CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
The FDA will consider the companion diagnostic application alongside data for Pfizer's talazoparib in BRCA-mutated advanced breast cancer.
The Center for Genomic Interpretation and NSGC want payors to cover confirmatory testing for patients with positive results from 23andMe's FDA-cleared test.
The funding will be available to members of the Association of Community Cancer Centers, a cancer care provider advocacy group.
A Phase III randomized trial uncovered enhanced carboplatin response in advanced triple-negative breast cancer patients with germline mutations affecting BRCA1/2.
Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.